Create
Log in
Sign up
Golden has been acquired by ComplyAdvantage.
Read about it here ⟶
US Patent 11857637 Anti-CD25 antibody-maytansine conjugates and methods of use thereof
Overview
Structured Data
Issues
Contributors
Activity
Access by API
Access by API
Is a
Patent
0
Date Filed
November 4, 2021
0
Date of Patent
January 2, 2024
0
Patent Application Number
17519183
0
Patent Citations
US Patent 11097013 Anti-HER2 antibody-maytansine conjugates and methods of use thereof
0
US Patent 10745464 Aldehyde tags, uses thereof in site-specific protein modification
0
US Patent 10888623 Hydrazinyl-indole compounds and methods for producing a conjugate
0
US Patent 7985783 Aldehyde tags, uses thereof in site-specific protein modification
0
US Patent 8097701 Aldehyde tags, uses thereof in site-specific protein modification
0
US Patent 8349910 Aldehyde tags, uses thereof in site-specific protein modification
0
US Patent 8729232 Aldehyde tags, uses thereof in site-specific protein modification
0
US Patent 8846866 Aldehyde tags, uses thereof in site-specific protein modification
0
US Patent 9238878 Aldehyde-tagged protein-based drug carriers and methods of use
0
US Patent 9310374 Hydrazinyl-indole compounds and methods for producing a conjugate
0
•••
Patent Inventor Names
David Rabuka
0
Penelope M. Drake
0
Patent Jurisdiction
United States Patent and Trademark Office
0
Patent Number
11857637
0
Patent Primary Examiner
Karen A. Canella
0
CPC Code
A61K 47/6889
0
A61K 47/6849
0
A61K 47/6803
0
C07K 16/2866
0
A61K 47/6867
0
Find more entities like US Patent 11857637 Anti-CD25 antibody-maytansine conjugates and methods of use thereof
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Company
Home
Press & Media
Blog
Careers
WE'RE HIRING
Products
Knowledge Graph
Query Tool
Data Requests
Knowledge Storage
API
Pricing
Enterprise
ChatGPT Plugin
Legal
Terms of Service
Enterprise Terms of Service
Privacy Policy
Help
Help center
API Documentation
Contact Us
SUBSCRIBE